|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||248.80 - 252.00|
|52-week range||149.00 - 254.00|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||40.29|
|Forward dividend & yield||1.69 (0.90%)|
|Ex-dividend date||26 Apr 2021|
|1y target est||N/A|
Germany's Merck KGaA, which is investing to catch up with ballooning demand for its biotech manufacturing supplies, said the order book in COVID-19 related lab gear was still growing faster than sales but it was getting a better handle on the situation. "We are really very well trained at this time to deal with the supply chain pressures... We have made tremendous progresses, however, our order book is still growing faster than our sales," Chief Executive Belen Garijo told journalists after releasing full quarterly results. "We are getting the situation back on track but it’s going to take a little bit of time to get each and every site up to the necessary targets to be able to fulfil 100% of customer demand," she said, adding that only single-use bioreactor equipment and filters were affected.
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
FRANKFURT (Reuters) -European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic. Germany's Merck KGaA, whose Life Science unit is one of the world's largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders. U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.